All in: No­var­tis adds an­oth­er drug to its fast-grow­ing ra­dio­phar­ma­ceu­ti­cals di­vi­sion

No­var­tis $NVS has struck the lat­est in a se­ries of deals to beef up its ra­dio­phar­ma­ceu­ti­cals group. 

Just weeks af­ter the phar­ma gi­ant snapped up En­do­cyte and its ra­dioiso­tope drug Lu-PS­MA-617 in a $2.1 bil­lion deal — adding it to the Ad­vanced Ac­cel­er­a­tor Ap­pli­ca­tions group it ac­quired a lit­tle more than a year ago for $3.9 bil­lion — its deal­mak­ing crew has added glob­al rights to a new ra­dio­phar­ma­ceu­ti­cal called FF-10158 for on­col­o­gy in­di­ca­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.